FDA Inspection 1249701 — Jeffrey M. Kaplan, M.D.
The FDA completed an inspection of Jeffrey M. Kaplan, M.D. on Sep 20, 2024 in Overland Park, KS. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 4 citations were issued during this inspection. Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Sep 20, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Overland Park, KS (United States)
Additional Details
Clinical Investigator (CI)
Citations
| ID | CFR | Description |
|---|---|---|
| 7363 | 21 CFR 50.55(f) | Documentation of permission by parents or guardian |
| 7367 | 21 CFR 50.55(e)(2) | Two parents' permission: studies under Parts 50.53 - 50.54 |
| 7530 | 21 CFR 312.62(b) | Case history records- inadequate or inadequate |
| 7560 | 21 CFR 312.60 | FD-1572, protocol compliance |